

PATENT
Attorney Docket No. 247/164CLEAN COPY OF AMENDED CLAIMS

- B1
Sub
C1
102
233
1. (Twice Amended) A method for treating an autoimmune disease of the mouth, comprising topically contacting the mouth of a patient in need of such treatment with a formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide, and optionally a non-steroidal anti-inflammatory agent.

- B2
102
19. (Twice Amended) A method for preventing an autoimmune disease of the mouth, comprising topically contacting the mouth of a patient in need of such treatment with a formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide, and optionally a non-steroidal anti-inflammatory agent.

- B3
37. (New) The method of claim 1, wherein said formulation further includes at least one member selected from the group consisting of hydrocortisone, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, triamcinolone acetonide, methylprednisolone, and prednisolone.

38. (New) The method of claim 1, wherein said formulation further includes at least one member selected from the group consisting of a cyclosporin, cyclophosphamide, FK-506, deoxyspergualin, thalidomide, methotrexate, bredinin, and didemnin B.

39. (New) The method of claim 1, wherein said non-steroidal anti-inflammatory agent is a member selected from the group consisting of indomethacin, sulindac, ibuprofen, aspirin, naproxen and tolmetin.